A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Trial Profile

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Ivosidenib (Primary)
  • Indications Acute myeloid leukaemia; Cholangiocarcinoma; Glioma; Myelodysplastic syndromes; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2018 Status changed from recruiting to completed.
    • 09 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 May 2018.
    • 09 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top